References- Eye Enhanced
- 1.Latkany R. Dry eyes: etiology and management. Curr Opin Ophthalmol. 2008;19:287–91. doi: 10.1097/ICU.0b013e3283023d4c. [DOI] [PubMed] [Google Scholar]
- 2.Fox RI, Stern M, Michelson P. Update in Sjögren’s syndrome. Curr Opin Rheumatol. 2000;12:391–8. doi: 10.1097/00002281-200009000-00007. [DOI] [PubMed] [Google Scholar]
- 3.DEW. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Workshop. Ocul Surf. 2007;5:75–92. doi: 10.1016/s1542-0124(12)70081-2. [DOI] [PubMed] [Google Scholar]
- 4.Luo L, Li DQ, Doshi A, et al. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthalmol Vis Sci. 2004;4:4293–301. doi: 10.1167/iovs.03-1145. [DOI] [PubMed] [Google Scholar]
- 5.Acera A, Rocha G, Vecino E, et al. Inflammatory markers in the tears of patients with ocular surface disease. Ophthalmic Res. 2008;40:315–21. doi: 10.1159/000150445. [DOI] [PubMed] [Google Scholar]
- 6.Pflugfelder SC, Farley W, Luo L, et al. Matrix metalloproteinase-9 knockout confers resistance to corneal epithelial barrier disruption in experimental dry eye. Am J Pathol. 2005;166:61–71. doi: 10.1016/S0002-9440(10)62232-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Yoon KC, De Paiva CS, Qi H, et al. Expression of Th-1 chemokines and chemokine receptors on the ocular surface of C57BL/6 mice: effects of desiccating stress. Invest Ophthalmol Vis Sci. 2007;48:2561–9. doi: 10.1167/iovs.07-0002. [DOI] [PubMed] [Google Scholar]
- 8.Tsubota K, Fukagawa K, Fujihara T, et al. Regulation of human leukocyte antigen expression in human conjunctival epithelium. Invest Ophthalmol Vis Sci. 1999;40:28–34. [PubMed] [Google Scholar]
- 9.Pisella PJ, Brignole F, Debbasch C, et al. Flow cytometric analysis of conjunctival epithelium in ocular rosacea and keratoconjunctivitis sicca. Ophthalmology. 2000;107:1841–9. doi: 10.1016/s0161-6420(00)00347-x. [DOI] [PubMed] [Google Scholar]
- 10.de Paiva CS, Pflugfelder SC. Rationale for anti-inflammatory therapy in dry eye syndrome. Arq Bras Oftalmol. 2008;71:89–95. doi: 10.1590/s0004-27492008000700017. [DOI] [PubMed] [Google Scholar]
- 11.Peral A, Domínguez-Godínez CO, Carracedo G, Pintor J. Therapeutic targets in dry eye syndrome. Drug News Perspect. 2008;21:166–76. [PubMed] [Google Scholar]
- 12.Donnenfeld E, Pflugfelder SC. Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol. 2009;54:321–38. doi: 10.1016/j.survophthal.2009.02.002. [DOI] [PubMed] [Google Scholar]
- 13.Pintor J, Peral A, Hoyle CH, et al. Effects of diadenosine polyphosphates on tear secretion in New Zealand white rabbits. J Pharmacol Exp Ther. 2002;300:291–7. doi: 10.1124/jpet.300.1.291. [DOI] [PubMed] [Google Scholar]
- 14.Tauber J, Davitt WF, Bokosky JE, et al. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. Cornea. 2004;23:784–92. doi: 10.1097/01.ico.0000133993.14768.a9. [DOI] [PubMed] [Google Scholar]
- 15.Stiles GL. Adenosine receptors and beyond: molecular mechanisms of physiological regulation. Clin Res. 1990;38:10–8. [PubMed] [Google Scholar]
- 16.Baharav E, Bar-Yehuda S, Madi L, et al. Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models. J Rheumatol. 2005;32:469–76. [PubMed] [Google Scholar]
- 17.Fishman P, Bar-Yehuda S, Madi L, et al. The PI3K–NF-κ B signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis. Arthritis Research &Therapy. 2006;8:1–9. doi: 10.1186/ar1887. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Rath-Wolfson L, Bar Yehuda S, Madi L, et al. IB-MECA, an A3 adenosine receptor agonist prevents bone resorption in rats with adjuvant induced arthritis. Clin & Exp Rheum. 2006;24:400–6. [PubMed] [Google Scholar]
- 19.Bar-Yehuda S, Silverman MH, Kerns WD, et al. The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis. Expert Opin Inves Drugs. 2007;16:1601–13. doi: 10.1517/13543784.16.10.1601. [DOI] [PubMed] [Google Scholar]
- 20.Mabley J, Soriano F, Pacher P, et al. The adenosine A3 receptor agonist, N6-(3-iodobenzyl)-adenosine-5’-N-methyluronamide, is protective in two murine models of colitis. Eur J Pharmacol. 2003;466:323–9. doi: 10.1016/s0014-2999(03)01570-x. [DOI] [PubMed] [Google Scholar]
- 21.Bar Yehuda S, Rat-Wolfson L, Del Valle L, et al. CF101 induces anti-inflammatory effect and prevents cartilage damage in rat knee osteoarthritis. Arthritis & Rheumatol accepted. 2009 doi: 10.1002/art.24817. [DOI] [PubMed] [Google Scholar]
- 22.Lee HT, Kim M, Joo JD, et al. A3 adenosine receptor activation decreases mortality and renal and hepatic injury in murine septic peritonitis. Am J Physiol Regul Integr Comp Physiol. 2006;291:R959–69. doi: 10.1152/ajpregu.00034.2006. [DOI] [PubMed] [Google Scholar]
- 23.van Troostenburg AR, Clark EV, Carey WDH, et al. Tolerability, pharmacokinetics, and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men. Int J Clin Pharmacol Ther. 2004;42:534–42. doi: 10.5414/cpp42534. [DOI] [PubMed] [Google Scholar]
- 24.Silverman MH, Strand V, Markovits D, et al. Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial. Rheumatol. 2008;35:41–8. [PubMed] [Google Scholar]
- 25.Schiffman RM, Christianson MD, Jacobsen G, et al. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000;118:615–21. doi: 10.1001/archopht.118.5.615. [DOI] [PubMed] [Google Scholar]
- 26.Cohen IJ. Use of fluorescein in the eye. J Occup Med. 1963;5:540–1. [PubMed] [Google Scholar]
- 27.Holland MC. Fluorescein staining of the cornea. JAMA. 1964;188:81. doi: 10.1001/jama.1964.03060270087025. [DOI] [PubMed] [Google Scholar]
- 28.Kellerman D, Rossi Mospan A, Engels J, et al. Denufosol: a review of studies with inhaled P2Y2 agonists that led to Phase 3. Pulm Pharmacol Ther. 2008;21:600–7. doi: 10.1016/j.pupt.2007.12.003. [DOI] [PubMed] [Google Scholar]
- 29.Carré DA, Mitchell CH, Peterson-Yantorno K, et al. Similarity of A3-adenosine and swelling-activated Cl(-) channels in nonpigmented ciliary epithelial cells. Am J Physiol Cell Physiol. 2000;279:C440–51. doi: 10.1152/ajpcell.2000.279.2.C440. [DOI] [PubMed] [Google Scholar]
- 30.Yang H, Avila MY, Peterson-Yantorno K, et al. The cross-species A3 adenosine-receptor antagonist MRS 1292 inhibits adenosine-triggered human nonpigmented ciliary epithelial cell fluid release and reduces mouse intraocular pressure. Curr Eye Res. 2005;30:747–54. doi: 10.1080/02713680590953147. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Do CW, Civan MM. Swelling-activated chloride channels in aqueous humour formation: on the one side and the other. Acta Physiol (Oxf) 2006;187:345–52. doi: 10.1111/j.1748-1716.2006.01548.x. [DOI] [PubMed] [Google Scholar]
- 32.Liu H, Begley CG, Chen M, et al. A link between tear instability and hyperosmolarity in dry eye. Invest Ophthalmol Vis Sci. 2009;50:3671–9. doi: 10.1167/iovs.08-2689. [DOI] [PubMed] [Google Scholar]
- 33.Yeo AC, Carkeet A, Carney LG, Yap MK. Relationship between goblet cell density and tear function tests. Ophthalmic Physiol Opt. 2003;23:87–94. doi: 10.1046/j.1475-1313.2003.00092.x. [DOI] [PubMed] [Google Scholar]
- 34.Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 2000;107:631–9. doi: 10.1016/s0161-6420(99)00176-1. [DOI] [PubMed] [Google Scholar]
